These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 24432999

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 4. Islet Function and Insulin Sensitivity in Latent Autoimmune Diabetes in Adults Taking Sitagliptin: A Randomized Trial.
    Yang L, Liang H, Liu X, Wang X, Cheng Y, Zhao Y, Liu L, Huang G, Wang X, Zhou Z.
    J Clin Endocrinol Metab; 2021 Mar 25; 106(4):e1529-e1541. PubMed ID: 33475138
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.
    Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, Astiarraga B, Chen Y, Alba M, Holst J, Ferrannini E.
    J Clin Endocrinol Metab; 2012 Aug 25; 97(8):2818-26. PubMed ID: 22685234
    [Abstract] [Full Text] [Related]

  • 6. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T, Fehér J.
    Orv Hetil; 2010 Jun 20; 151(25):1012-6. PubMed ID: 20519186
    [Abstract] [Full Text] [Related]

  • 7. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA).
    Zhou Z, Li X, Huang G, Peng J, Yang L, Yan X, Wang J.
    Diabetes Metab Res Rev; 2005 Jun 20; 21(2):203-8. PubMed ID: 15386806
    [Abstract] [Full Text] [Related]

  • 8. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA).
    Li X, Liao L, Yan X, Huang G, Lin J, Lei M, Wang X, Zhou Z.
    Diabetes Metab Res Rev; 2009 Jul 20; 25(5):411-6. PubMed ID: 19488999
    [Abstract] [Full Text] [Related]

  • 9. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
    Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK.
    Endocr Pract; 2013 Jul 20; 19(1):19-28. PubMed ID: 23186950
    [Abstract] [Full Text] [Related]

  • 10. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP.
    Diabetes Obes Metab; 2007 Mar 20; 9(2):186-93. PubMed ID: 17300594
    [Abstract] [Full Text] [Related]

  • 11. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.
    J Clin Endocrinol Metab; 2006 Nov 20; 91(11):4612-9. PubMed ID: 16912128
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct 20; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 13. Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on β-cell function in a newly designed two-step hyperglycemic clamp.
    Zhang Y, Chi J, Wang W, Hong J, Gu W, Wang B, Ning G.
    J Diabetes; 2015 Mar 20; 7(2):213-21. PubMed ID: 24889731
    [Abstract] [Full Text] [Related]

  • 14. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
    Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, Moller DE, Thornberry NA, Zhang BB.
    Diabetes; 2006 Jun 20; 55(6):1695-704. PubMed ID: 16731832
    [Abstract] [Full Text] [Related]

  • 15. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
    Zambrowicz B, Ding ZM, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Smith M, Ruff D, Sands A, Powell D.
    Clin Ther; 2013 Mar 20; 35(3):273-285.e7. PubMed ID: 23433601
    [Abstract] [Full Text] [Related]

  • 16. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
    Giampietro O, Giampietro C, Bartola LD, Masoni MC, Matteucci E.
    Drug Des Devel Ther; 2013 Mar 20; 7():99-104. PubMed ID: 23439744
    [Abstract] [Full Text] [Related]

  • 17. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B, Monnier L, Serusclat P, Petit C, Valensi P, Huet D, Raccah D, Colette C, Quéré S, Dejager S.
    Diabetes Metab; 2012 Oct 20; 38(4):359-66. PubMed ID: 22809630
    [Abstract] [Full Text] [Related]

  • 18. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B.
    Drugs Today (Barc); 2007 Jan 20; 43(1):13-25. PubMed ID: 17315049
    [Abstract] [Full Text] [Related]

  • 19. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).
    Gallwitz B.
    Drugs Today (Barc); 2007 Nov 20; 43(11):801-14. PubMed ID: 18174966
    [Abstract] [Full Text] [Related]

  • 20. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
    Alba M, Sheng D, Guan Y, Williams-Herman D, Larson P, Sachs JR, Thornberry N, Herman G, Kaufman KD, Goldstein BJ.
    Curr Med Res Opin; 2009 Oct 20; 25(10):2507-14. PubMed ID: 19691426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.